Confluence Pharmaceuticals LLC is a biotechnology and pharmaceutical startup founded in 2010 in the United States. The company is dedicated to developing innovative therapeutic medications for neurological development disorders, with a current focus on advancing a novel drug discovery aimed at improving social and communication impairments in individuals with Autism Spectrum Disorders and Fragile X Syndrome. Their latest funding round saw a $200.00K investment from IU Ventures on 17 June 2022. This investment is a testament to the potential that Confluence Pharmaceuticals holds in addressing critical unmet medical needs in the field of neurological disorders, and it underscores the confidence that prominent investors have in the company's innovative approach to drug development.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $200.00K | 1 |
|
17 Jun 2022 |
| Convertible Note | $100.00K | 1 |
|
02 Dec 2020 |
| Venture Round | $200.00K | 1 | Indiana University Philanthropic Venture Fund | 12 Apr 2019 |
| Venture Round | $250.00K | 1 | Purdue Research Foundation | 20 Dec 2018 |
| Venture Round | $1.30M | 1 |
|
20 Sep 2016 |
No recent news or press coverage available for Confluence Pharmaceuticals LLC.
We care about your data, and we'd love to use cookies make your experience better.
